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The emergence and spread of artemisinin resistance, driven by mutations in Plasmodium
falciparum K13, has compromised antimalarial efficacy and threatens the global malaria
elimination campaign. By applying systems-based quantitative transcriptomics, proteomics,
and metabolomics to a panel of isogenic K13 mutant or wild-type P. falciparum lines, we
provide evidence that K13 mutations alter multiple aspects of the parasite’s intra-erythrocytic
developmental program. These changes impact cell-cycle periodicity, the unfolded protein
response, protein degradation, vesicular trafficking, and mitochondrial metabolism. K13-
mediated artemisinin resistance in the Cambodian Cam3.II line was reversed by atovaquone,
a mitochondrial electron transport chain inhibitor. These results suggest that mitochondrial
processes including damage sensing and anti-oxidant properties might augment the ability of
mutant K13 to protect P. falciparum against artemisinin action by helping these parasites
undergo temporary quiescence and accelerated growth recovery post drug elimination.
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P lasmodium falciparum parasites, the primary etiologicalagent of severe malaria, caused an estimated 229 millionclinical cases and 409,000 deaths in 2019, predominantly in
young African children1. Disease is caused by the asexual blood
stages, which complete their intra-erythrocytic developmental
cycle (IDC) every ~48 h. Globally, first-line treatment depends on
artemisinin (ART)-based combination therapies (ACTs), which
benefit from the exceptional potency of ART derivatives. These
derivatives are activated in the parasite by hemoglobin-derived
Fe2+-heme and kill rings and trophozoites via alkylation of
proximal proteins, lipids, and heme2–4. P. falciparum resistance to
ART, which first emerged in western Cambodia, is now present
across the Greater Mekong Sub-region (GMS), compromising
clinical efficacy5–7. Clinically, resistance is defined as a >5.5 h
parasite clearance half-life (i.e. the time required to halve the
parasite biomass)8,9. This reduced rate of clearance has increased
the selective pressure on the partner drug. The recent appearance
and spread across the GMS of resistance to the first-line partner
drug piperaquine in ART-resistant parasites is causing wide-
spread treatment failures, threatening local malaria control
efforts9–11. A spread of ART resistance in Africa would be
devastating12.
Genetic and clinical data, supported by gene editing experi-
ments, have identified point mutations in K13 (also known as
Kelch13) as the dominant causal determinant of ART resistance.
The degree of resistance is modulated by the specific mutation,
which tends to cluster geographically7,13, as well as by the parasite
genetic background14–19. With cultured parasites, resistance (or
tolerance) is typically defined as >1% survival in the Ring-stage
Survival Assay (RSA), in which young rings (0–3 h post invasion
(hpi)) are exposed to 700 nM DHA for 4–6 h and their survival
measured 3 days later as a percentage of mock-treated parasites20.
K13 R539T confers the highest level of in vitro resistance across
strains (19–49% survival, with a geometric mean survival of 27%,
as determined with four gene-edited strains), and is quite wide-
spread at a relatively low prevalence across Asia21. By comparison
K13 C580Y, which is the dominant isoform in the GMS, gives a
more moderate in vitro resistance phenotype (4–24% survival,
with a geometric mean survival of 9.2%, as determined with five
gene-edited strains)16,22. K13-independent ART resistance has
also been documented in five field isolates originating from
Cambodia or Senegal and in two independent selection or
transfection studies with the 3D7 parasite line23–26.
The biological role of K13 and the precise mechanism(s) by
which its mutations elicit an enhanced survival response to ART
remain enigmatic. Studies have suggested roles for reduced
endocytosis of hemoglobin leading to less Fe2+-heme and
reduced drug activation in rings, an endoplasmic reticulum (ER)
stress response and an up-regulated unfolded protein response,
translational arrest possibly involving enhanced eIF2-α phos-
phorylation, decreased levels of protein ubiquitination and altered
rates of proteasome-mediated protein turnover, and PI3K-
dependent intracellular signaling linked to amplified PI3P vesi-
cles27–35. These processes could offset widespread ART-mediated
damage to parasite proteins and other biomolecules36,37. One
pressing question is whether these cellular effects are a direct
result of mutations in K13, or whether they are epistatic phe-
nomena that provide suitable cellular contexts on which mutant
K13 can exert ART resistance, or a combination of both.
In this work, to explore the impact of K13 mutations on the
parasite and gain further insight into the mechanism of ART
resistance, we subjected a panel of k13 gene-edited isogenic
parasites on two different genetic backgrounds to untargeted
multi-omics including transcriptomics, proteomics, and meta-
bolomics (Fig. 1). Results provided herein reveal a broad array of
intracellular processes affected by K13 mutations and converge
on a previously unsuspected role for mitochondria. These data
reveal vulnerabilities that could be leveraged to target ART-
resistant P. falciparum.
Results
K13 mutations rewire the P. falciparum transcriptome. To
investigate the biological function of K13, we examined the
transcriptional profiles of highly synchronized K13 mutant or
isogenic wild-type (WT) parasite lines generated in the pre-ART
era Dd2 and contemporary Cam3.II SE Asian strains16
(Dd2R539T, Dd2C580Y, Dd2WT, Cam3.IIR539T, and Cam3.IIWT)
across the 48 h IDC time course (Fig. 1, Table 1 and Supple-
mentary Fig. 1a). Between k13 genotypes, the Dd2 and Cam3.II
sets of parasites mapped to highly similar IDC time points, with
the isogenic sets of lines differing in developmental age by up to
1.5 and 4 h, respectively at the 0 h start of sampling. Principal
component analyses of transcriptomic profiles showed distinct
clustering by parasite stage (0–16 hpi rings vs. 24–40 hpi tro-
phozoites and schizonts for PC1; trophozoites vs. schizonts for
PC2), followed by genetic background (PC3) (Fig. 2a). Variation
between strains outweighed the impact of K13 mutations on the
transcriptomes, underscoring the need to compare isogenic edited
parasites in order to identify changes specifically attributable to
k13 sequence variants.
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Fig. 1 Outline of experimental workflow and multi-omics approaches
applied to examine K13 function in this study. The workflow illustrates the
sample collection, processing, and data acquisition steps. The Dd2
laboratory-adapted parasite line and the Cam3.II clinical isolate were
genetically modified at the k13 locus via zinc-finger nuclease-based gene
editing to create isogenic lines with either the wild-type (WT) or mutant k13
alleles15. RNA, protein, or metabolite samples were collected for each
parasite line at 6–7 time points throughout the 48 h asexual blood stage
cycle in the absence of drug treatment. Synchronized K13 mutant and WT
parasites were also subjected to a pulse of DHA, either at a concentration
of 350 nM for 3 h (for metabolomics) or at 700 nM for 6 h (for
transcriptomics), in parallel with 0.1% DMSO vehicle control. Samples were
collected during DHA exposure and post drug removal. Colored arrows
represent times and conditions of harvest for the different omic methods
(green for transcriptomics, orange for proteomics and purple for
metabolomics). Using microarray gene expression profiling and quantitative
mass spectrometry-based proteomics and metabolomics, we generated
global transcriptional, proteomic, and metabolomic profiles of gene-edited
lines and compared the K13 mutants to their isogenic WT counterparts
across the IDC.
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Because K13 mutations have been previously linked to
prolonged duration of ring-stage development29,38, we used
Spearman rank correlations to map parasite ages to a high-
resolution 96-time point reference transcriptome (Supplementary
Fig. 1b–f). While the R539T mutants and WT parasites
progressed similarly in both Dd2 and Cam3.II parasite back-
grounds, the Dd2C580Y mutant developed ~4 h slower, most
evident at the 24, 32, and 48 h time points (***P < 0.001, t-test,
N= 3) (Fig. 2b and Supplementary Fig. 2a). This finding suggests
that Dd2C580Y has a longer ring phase with a delayed ring to
trophozoite transition.
At each sampling time point across the 48 h IDC, we observed
~80–200 genes differentially expressed (DE) between the
Dd2R539T mutant line and its isogenic Dd2WT counterpart (P <
0.05, t-test, n= 3). Similar numbers of DE genes were observed in
Dd2C580Y rings, with even higher numbers of DE genes observed
at later time points (24, 32, and 48 h; Supplementary Fig. 2b and
Supplementary Data 1), due to the decelerated development of
Dd2C580Y parasites. A significant overlap of 394 genes were DE in
the Dd2R539T and Dd2C580Y lines relative to Dd2WT parasites. Of
these genes, 123 and 113 were up- and down-regulated,
respectively, in both mutants within the same 4 h developmental
window of the IDC (Fig. 2c). K-means clustering of the 394 DE
genes showed a similar pattern of differential expression elicited
by both mutants, indicating that the two different K13 mutations
impacted expression of these genes in the same manner (Fig. 2c).
Most of these DE genes in Dd2 parasites were up-regulated during
the transition from late schizonts to early rings and were enriched for
pathways specialized in ubiquitin transfer (including ubiquitin-
conjugating enzyme E2 and HECT-domain ubiquitin-transferase),
protein phosphorylation, intracellular signaling (including adenylyl
cyclase and cAMP protein kinase), sphingolipid and ceramide lipid
metabolism, and mitochondrial electron transport chain (ETC)
NADH dehydrogenase ubiquinone activity (hypergeometric test; P <
0.05) (Fig. 2d; Supplementary Fig. 2d and Data 1 and 2).
These same DE pathways were also observed in the Cam3.
IIR539T mutant. Interestingly, k13 was among this set of genes
with higher transcript abundance in the K13 mutant early rings.
Functional enrichment analysis of DE genes at each sampling
time point through the IDC for Dd2 and Cam3.II identified other
strain-transcending changes associated with K13 mutations,
ranging from elevated histone modifications in late rings, to
higher levels of pyruvate metabolic enzyme, phosphoenolpyruvate
(PEP) carboxykinase, and exported parasite proteins to the host
red blood cell (RBC) cytosol in trophozoites, and increased S-
nitrosylation and palmitoylation-modified proteins in schizonts
(Fig. 2d and Supplementary Data 2). Several pathways were also
exclusive to K13 mutants in Dd2 but not Cam3.II, including the
DNA damage checkpoint (GO process) that contained genes that
were up-regulated in ring stages in both Dd2 K13 mutant lines
compared to Dd2WT.
K13 mutations alter the parasite proteome including protein
turnover and glutamate and purine metabolism. In parallel, we
performed isobaric labeling-based quantitative proteomics with
Cam3.II lines (Cam3.IIR539T, Cam3.IIC580Y, and Cam3.IIWT),
and detected a total of 2780 and 2573 proteins (~50% of the P.
falciparum proteome) in synchronized rings and trophozoites,
respectively (N= 2; Fig. 1 and Supplementary Fig. 3a). Strikingly,
fewer proteins were DE between K13 mutant and WT parasites in
trophozoites, as compared to early rings that manifest ART
resistance (Fig. 3a and Supplementary Fig. 3b, b). In rings, 87
proteins were more abundant in both K13 mutants relative to the
isogenic WT line, in at least one experiment (P < 0.05; t-tests
using normalized spectral intensity of peptides for each protein;
Fig. 3a and Supplementary Data 3). Functional enrichment ana-
lyses converged on chaperone-mediated protein folding (cyclo-
philin 19B, ER calcium-binding protein, chaperonin 10 kDa) and
protein targeting processes in the proteasome core complex
(proteasomal subunits and ubiquitin ligase), redox (superoxide
dismutase), and processes within intracellular vesicles and the
digestive vacuole (Fig. 3a).
Of note, cyclophilin 19B was the top hit associated with in vivo
ART resistance from an earlier transcriptomics study of P.
falciparum clinical isolates29. Our observations here suggest that
its increased protein abundance is regulated by K13 mutations.
We also observed new functionalities not previously associated
with K13, including carbon metabolism (illustrated by the
increased abundance of glutamine synthetase and NADP-
specific glutamate dehydrogenase that both help regulate cellular
glutamine levels), as well as adenosine deaminase and
hypoxanthine-guanine phosphoribosyltransferase (HGXPRT),
which are critical for purine metabolism (Supplementary Data 3).
While the changes associated with K13 mutations in rings were
mostly instances of increased abundance, all 13 DE proteins in
trophozoites showed reduced levels in the K13 mutants
(Supplementary Fig. 3c). This included 1.8- to 2.0-fold less K13
protein in Cam3.IIC580Y and Cam3.IIR539T trophozoites (Fig. 3b),
as previously reported39. However, unlike Cam3.IIR539T rings that
showed 1.5-fold reduced K13 protein, there was no detectable
difference in Cam3.IIC580Y rings (Fig. 3b). In these samples, K13
was identified with 11 unique peptides, covering 17% of the
protein (Supplementary Fig. 4). The increased turnover of K13
protein in Cam3.IIR539T rings may contribute to this parasite
line’s relatively high degree of ART resistance and suggests a
potential loss-of-function role for the R539T mutation.
Targeted metabolomics reveals altered levels of tricarboxylic
acid (TCA) cycle and purine salvage metabolites in K13
mutants. Metabolomic analyses of Cam3.IIC580Y and Cam3.IIWT
ring (N= 3) and trophozoite (N= 1) extracts, using a previously
published dataset40, detected a total of 96 metabolites
Table 1 Geographic origin, k13 isoform, and DHA response of P. falciparum lines.
Parasite Edited? K13 Origin (year) PCt1/2 (h) RSA (% survival) Omics method
Cam3.IIR539T No R539T Pursat, W. Cambodia (2010) 6.0 40.2 ± 3.0 Transcriptomics, proteomics, co-IP
Cam3.IIC580Y Yes C580Y Pursat, W. Cambodia (2010) N/A 24.1 ± 2.9 Proteomics, co-IP, metabolomics
Cam3.IIWT Yes WT Pursat, W. Cambodia (2010) N/A 0.3 ± 0.1 Transcriptomics, proteomics, co-IP,
metabolomics
Dd2R539T Yes R539T Indochina (1980) N/A 19.4 ± 0.8 Transcriptomics
Dd2C580Y Yes C580Y Indochina (1980) N/A 4.1 ± 0.4 Transcriptomics
Dd2WT Yes (bsm) WT Indochina (1980) N/A 0.3 ± 0.1 Transcriptomics
bsm binding-site mutant control (no amino acid substitutions), co-IP co-immunoprecipitation, N/A not available, PCt1/2 parasite clearance half-life, RSA Ring-stage Survival Assay conducted with 0–3 h
post invasion rings, WT wild type. Cam3.II and Dd2 parasites both harbor the PfCRT Dd2 haplotype: M74I/N75E/K76T/A220S/Q271E/N326S/I356T/R371I. Dd2 and Cam3.II harbor the PfMDR1
haplotypes N86Y and Y184F, respectively.
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(Supplementary Fig. 5a and Supplementary Data 4). Sample-to-
sample correlation of the metabolite expression profiles showed
that ring-stage samples clustered separately from trophozoites
and uninfected RBC controls, indicating substantial changes in
parasite metabolism throughout the IDC (Supplementary
Fig. 5b). Metabolomic set enrichment analyses of untreated ring-
stage parasites revealed that the C580Y mutation affected the
basal levels of metabolites involved in the TCA cycle, as well as
purine, glutamate, and pyruvate metabolism (Fig. 3c). Partial
least-squares discriminant analyses revealed several metabolites
Fig. 2 K13 mutations associate with altered temporal cell-cycle progression and broad transcriptional changes throughout the 48 h IDC. a PCA plots
for transcriptome samples labeled by parasite line, K13 status, sampling time, and parasite asexual stage. This analysis was conducted on Cam3.II and Dd2
K13 WT, C580Y and R539T samples, as well as the Cam2 isogenic K13 C580Y and WT pair16. b Transcriptomics-based age estimation for R539T and
C580Y mutants and isogenic WT Dd2 parasites determined by comparison against a Dd2 reference 48 h IDC68. Dd2C580Y mutant parasites showed a
significant albeit modest (up to 4 h) slowing of the developmental cycle during the 16–48 h developmental period, relative to Dd2WT and Dd2R539T
parasites. Each time point was harvested on three independent occasions (data points are presented as means ± SEM), except for the 16 h time point that
was collected only once. Differences between lines were examined using a two-sided t-test; ***P < 0.001. P values for each comparison were 24 h time
point–Dd2C580Y vs. Dd2WT P= 1.7E−6, Dd2C580Y vs. Dd2R539T P= 5.1E−5; 32 h time point–Dd2C580Y vs. Dd2WT P= 1.7E−6, Dd2C580Y vs. Dd2R539T P=
2.6E−5; 48 h time point–Dd2C580Y vs. Dd2WT P= 0.002. c Venn diagram (right) showing significant overlap of 394 DE genes in pair-wise comparisons
between the gene-edited K13 mutant and WT lines at the same developmental stage (± 4 h). Heat map of k means-clustered overlapping DE genes in each
pair-wise comparison, showing a similar profile of differential expression in both the R539T and C580Y mutants as compared to the WT line. Significant
changes in expression levels were defined using a two-sided t-test (P < 0.05). Results also revealed consistent up-regulation of 80 genes in the 48 h late
segmenter/early ring-stage samples of both K13 mutant parasite lines (see lower rows; detailed in Supplementary Data 1). The Venn diagram analysis used
a binomial distribution test, with P= 5.7E−32. d Significantly up-regulated gene sets common to both K13 mutants relative to WT parasites
(hypergeometric testing, P < 0.05) across the 48 h cycle in both the Cam3.II and Dd2 backgrounds (see Supplementary Data 2). ETC electron transport
chain, hpi hours post invasion, PEP phosphoenolpyruvate, PTMs post-translational modifications.
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with differential levels between the mutant and WT parasite
(Supplementary Fig. 5c, d). The Cam3.IIC580Y parasite had lower
levels of malate and 2-ketoglutarate, both of which serve as TCA
cycle intermediates, and N-acetyl glutamate, a glutamate meta-
bolite, consistent with higher NADP-specific glutamate dehy-
drogenase and glutamine synthetase RNA transcripts in the
mutant lines (Fig. 3c). In contrast, we observed higher levels of
the nucleoside precursor inosine 5′-diphosphate and pyruvate
metabolite phosphoenolpyruvate (PEP). These findings were
consistent with higher HGXPRT protein abundance and elevated
PEP carboxykinase RNA transcript levels (Fig. 2d and Supple-























































































































































































































































































Fig. 3 K13 mutations associate with differential expression of proteins involved in proteasome-mediated turnover and protein folding, and altered
levels of TCA cycle, purine, glutamate, and pyruvate metabolites at the ring stage. a Heat map of the log2 fold change of significantly different protein
levels in Cam3.IIR539T or Cam3.IIC580Y mutants relative to the isogenic Cam3.IIWT parasites for 155 DE proteins identified from isobaric labeling-based
quantitative proteomics. Within each biological replicate, two- sided t-tests were performed for peptide levels belonging to each protein between K13
mutant and WT isogenic lines. Word cloud representation of functional analysis of significant biological processes and cellular components (Gene
Ontology database) for the 87 up-regulated proteins in K13 mutant rings, along with their corresponding P values. b Relative fold change of K13 protein
levels in Cam3.IIR539T and Cam3.IIC580Y mutants vs. Cam3.IIWT, at the ring and trophozoite stages. K13 protein was ~2-fold lower in the Cam3.IIR539T rings
and trophozoites, as compared to the isogenic Cam3.IIWT line. Data points are shown with means of the averaged normalized peptide abundance across
two independent experiments for each strain and stage, except for C580Y trophozoites. c Scatterplot of the enrichment –log10 P score (using a two-sided t-
test adjusted for multiple comparisons using the Holm–Bonferroni method) of the metabolite pathway and % pathway impact calculated from metabolite
set enrichment analysis comparing Cam3.IIC580Y and Cam3.IIWT rings at basal level. Differential expression of four pathways (P < 0.05; gold color) is
shown. Circle sizes reflect the pathway impact value, which represents the cumulative percentage of matched metabolite nodes (i.e. the importance
measure) with respect to the total pathway based on pathway topological analyses. Box plots show reduced normalized log2 levels of the two TCA cycle
metabolites, malate, and 2-ketoglutarate, and the glutamate metabolite, N-acetyl glutamate, but increased level of the purine metabolite, inosine 5′-
diphosphate in Cam3.IIC580Y as compared to Cam3.IIWT rings. Data are represented as box and whisker plots with medians, interquartile ranges, and 95%
confidence intervals (N= 3 independent experiments). d Interactome network of the 21 putative K13-interacting partners detected by co-
immunoprecipitation (co-IP) with the K13-specific monoclonal antibodies E3 and D9 (ref. 41) and mass spectrometry experiments using K13 WT, C580Y,
or R539T samples from either the Cam3.II or CamWT strain background16. Proteins were clustered using the Markov Cluster Algorithm in STRING. Line
thickness depicts the confidence/strength of the relationship between proteins (nodes). Solid lines represent intra-cluster interactions while dashed lines
represent the interaction between clusters. Red nodes correspond to mitochondrial proteins, which are over-represented in this list of co-IP proteins. Gene
abbreviations are listed in Supplementary Data 5.
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higher reliance on reverse glutaminolysis, with alterations in
glycolysis/gluconeogenesis, the mitochondrial TCA cycle, and
purine metabolism in the K13 mutants.
Co-immunoprecipitation assays identify mitochondrial factors
as major putative K13-interacting partners. To identify putative
interactors of K13 that could drive these RNA, protein, or
metabolomic changes described above, we earlier performed co-
immunoprecipitation (co-IP) and mass spectrometry experiments
using custom-raised K13-specific monoclonal antibodies on k13-
edited and WT Cambodian isolates. The specificity of these
antibodies was validated using western blot and IFA data com-
paring our K13 signals with results from parasite lines expressing
GFP-K13 or 3×HA tagged K13 (ref. 41). These experiments
yielded 21 proteins that were present in at least half of the six co-
IP experiments, and absent in four negative resin controls.
Interactome analyses using the STRING database, which uses
published biological data to search for observed and predicted
protein–protein interactions42, predicted a statistically significant
enrichment for interactions among these proteins
(protein–protein interaction P value of 3.1E−7) (Fig. 3d and
Supplementary Data 5). Besides identifying physical associations
of K13 with chaperones involved in protein folding and vesicle
trafficking, we also observed an over-representation of
mitochondrial-localized proteins (in 9 of 21 proteins; Fig. 3d, red
nodes). These proteins are important for a range of mitochondrial
functions including the TCA cycle (fumarate hydratase and
multiple 2-oxoglutarate dehydrogenase components), the ETC
(cytochrome bc1 complex), translation (elongation factor Tu),
Fe–S protein synthesis (ferrodoxin reductase-like protein), and
antioxidant processes (thioredoxin peroxidase 2). This evokes a
potential functional interplay between mitochondrial metabolism,
signaling, and the unfolded protein response in P. falciparum.
Metabolomic and transcriptional response of K13 parasites to
DHA. We next applied metabolomics and transcriptomics
approaches to explore the response of K13 lines to DHA expo-
sure. Metabolomic profiling of parasites after a 3 h treatment with
70 or 350 nM DHA revealed a substantial reduction in the levels
of several hemoglobin-derived peptides (including LD, SD, PE,
PD, PEE, DLS, DLH, and PVNF) in Cam3.IIC580Y and Cam3.
IIWT (Fig. 4a). This reduction was of a similar magnitude in both
Cam3.II K13 mutant and WT lines at ring and trophozoite stages.
In the absence of DHA, there was no difference in hemoglobin-
derived peptides levels between Cam3.IIC580Y and Cam3.IIWT
rings (Supplementary Fig. 5f). This finding suggests that the
reduction in hemoglobin-derived peptides upon treatment with
DHA occurs via a K13-independent mechanism, involving either
the inhibition of hemoglobin uptake or its digestion by the
parasite.
Mutant K13 promotes recovery after initial cell-cycle arrest in
DHA-treated parasites. To further characterize the effects of
DHA on cell-cycle progression and the protection afforded by
K13 mutations, early ring-stage parasites were subjected to a 6 h
pulse of 700 nM DHA or 0.1% DMSO vehicle control and sam-
ples were collected during and after DHA exposure (Fig. 1).
Transcriptional profiling and age mapping of WT and mutant
lines ± DHA using Spearman rank correlations revealed that
DHA-sensitive K13 WT parasites were completely halted in their
developmental progression over the period of 6–48 h post DHA
treatment (Fig. 4b, c, see solid purple and green lines, and Sup-
plementary Fig. 1b–f). In contrast, DHA-resistant K13 mutants
stalled for up to 16 h from the start of treatment and then
resumed normal cell-cycle development asynchronously (Fig. 4b,
c—see solid aqua, blue, and orange lines). The speed of re-
initiation of transcriptional activity correlated with the degree of
parasite’s resistance to ART afforded by the K13 mutation in the
Dd2 and Cam3.II backgrounds (Fig. 4b, c). Developmental dif-
ferences were independently verified by Giemsa smears. Mor-
phologically, we observed that DHA-treated K13 WT parasites
failed to develop beyond rings, with pyknotic forms seen 24 h
post DHA treatment. In contrast, a subset of DHA-treated K13
mutant parasites recovered after the initial drug-induced devel-
opmental arrest, progressed to schizonts, and reinvaded RBCs to
form new rings (Fig. 4d and Supplementary Fig. 6).
Differential transcriptional response of K13 mutants and WT
lines to DHA treatments. Compared to the transcriptional
impact of K13 mutations, DHA treatment affected a much larger
number of genes, up to 2530 and 2517 in K13 WT Dd2 and
Cam3.II parasites respectively (at P < 0.05; with cutoffs of >1.4-
fold for either Dd2 or Cam3.II). These transcriptional changes
occurred mostly at 32–40 h post treatment (Supplementary
Fig. 7). Gene set enrichment analyses with Dd2WT rings revealed
that pathways relating to protein metabolism such as protein
ubiquitination, degradation, folding, and translation, as well as
redox and glycolysis, were significantly down-regulated within 6 h
of initiating DHA treatment (P < 0.05 and false discovery rate
<0.3; Supplementary Data 6). Our observations agree with a prior
report that DHA treatment of K13 WT drug-sensitive parasites
caused a rapid drug-triggered shutdown in critical cellular pro-
cesses43. We note that fewer genes were DE in K13 mutants vs.
WT parasites after DHA exposure and the transcriptional chan-
ges in these genes were attenuated (Supplementary Fig. 7).
To identify genes that associate with the survival of post DHA-
pulsed K13 mutant parasites, we applied two-factor ANOVA on
transcriptional responses in the Dd2 and Cam3.II lines, stratified
by K13 status (mutant vs. WT) and treatment condition (DHA
vs. DMSO control). In total, 667 and 192 genes were DE from 3 to
48 h post initiation of DHA treatment in Dd2 or Cam3.II mutants
vs. their WT counterparts respectively (Fig. 4e and Supplemen-
tary Data 7). We observed a larger divergence in transcriptional
response to DHA between Dd2R539T and Dd2WT than between
Dd2C580Y and Dd2WT (Fig. 4e), consistent with the higher
survival rate in the R539T mutant compared with C580Y. Further
analyses of the initial 3 and 6 h post DHA/DMSO transcriptional
responses in Dd2R539T parasites that associated with elevated
survival in the early ring stage identified 348 and 234 genes with
higher and lower RNA expression, respectively, in the DHA-
treated Dd2R539T mutant relative to the Dd2WT line (t-test; P <
0.05) (Fig. 4f). Functional enrichment analyses revealed highly
similar up-regulated gene sets at the initial 6 h time point and
throughout the 48 h sampling, including Rab-mediated vesicular
trafficking (Rab 1A, 5B, and 11A), secretory and endocytic
complexes, organellar transcription, and mitochondrial ATP
production (Fig. 4f and Supplementary Fig. 8a). These pathways
were also observed in analyses of DHA-treated Cam3.IIR539T vs.
WT lines (Supplementary Fig. 8a, indicated with #, and
Supplementary Data 7). Gene sets specific to 6 h response
comprise tRNA modifications and lipid transport and those at 48
h in both backgrounds were limited to redox and DNA excision
repair. In contrast, fewer commonalities were seen between
down-regulated genes in DHA-treated K13 mutants as compared
to WT parasites, in both parasite backgrounds (Supplementary
Fig. 8b and Supplementary Data 7). Genes down-regulated in
DHA-treated Dd2R539T vs. Dd2WT from 6 to 48 h were enriched
for protein folding and ER heat-shock chaperones, autophagy
markers (ATG7 and ATG18), and phosphorylated proteins
(Fig. 4f). At the 6 h time point, we observed down-regulation of
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Differentially expressed gene sets in 
DHA-treated Dd2R539T vs. Dd2WT at 6h (P<0.05)
Fig. 4 Short-term DHA exposure results in a decrease of hemoglobin-derived peptides, and a temporary, reversible cell-cycle arrest in K13 mutant
parasites, concomitant with distinct transcriptional responses between K13 mutant and WT parasites. a Heat map of log2 fold changes in DHA-treated
Cam3.IIC580Y or Cam3.IIWT parasites vs. DMSO controls for the eight metabolites that showed a significant change in level after parasites were pulsed
with either 70 or 350 nM DHA for 3 h. DHA treatment at rings and trophozoites resulted in a consistent down-regulation of host hemoglobin-derived
peptides in both lines. For levels in untreated rings, see Supplementary Fig. 4f. b, c Transcriptome-based age estimation of the k13-edited R539T, C580Y,
and WT in Dd2 or Cam3.II parasites after 6 h pulsed exposure to either 700 nM DHA (solid lines) or DMSO vehicle control (dashed lines). Parasites were
sampled up to 48 h post treatment and developmental ages were determined using Spearman rank correlations. Results shown as means ± SEM (N= 3 for
each Dd2 line and N= 1 for Cam3.II lines). ***P < 0.001, unpaired two-sided t-tests. P values in b are: 24 h time point—Dd2WT DHA vs. DMSO P= 1.7E−5,
Dd2C580Y DHA vs. DMSO P= 1.7E−5, Dd2R539T DHA vs. DMSO P= 4.7E−6; 32 h time point—Dd2WT DHA vs. DMSO P= 2.5E−6, Dd2C580Y DHA vs.
DMSO P= 2.4E−6, Dd2R539T DHA vs. DMSO P= 0.002; 48 h time point—Dd2WT DHA vs. DMSO P= 3.7E−9, Dd2R539T DHA vs. DMSO P= 3.8E−6.
d Giemsa-stained parasite images showed that DHA-treated Cam3.IIWT parasites became pyknotic after 24 h, whereas Cam3.IIR539T parasites underwent
a lag in progression through the IDC following DHA treatment, compared to DMSO mock-treated controls. These images are representative of the majority
(>50%) of parasites observed at each time and condition per parasite line, with additional examples provided in Supplementary Fig. 6. Microscopy
analyses were performed for at least 5000 cells counted across three independent experiments, which yielded similar results. e Heat map of log2 ratios of
DHA-treated/DMSO-treated mRNA expression levels for the 667 hierarchically clustered genes whose expression differed significantly in the Dd2C580Y
and/or Dd2R539T mutants as compared with Dd2WT parasites across 3–48 h post initiation of treatment (N= 3 independent experiments; two-factor
ANOVA with adjusted P < 0.05; pathways listed in Supplementary Fig. 6 and Supplementary Data 7). A more divergent transcriptional response was
observed with Dd2R539T parasites that display high levels of ART resistance in vitro compared with Dd2C580Y parasites16. f Functional enrichment analyses
identified biological pathways significantly enriched (P < 0.05, hypergeometric tests) among the genes that were up- or down-regulated in the DHA-
treated Dd2R539T as compared with Dd2WT parasites relative to DMSO controls in early rings after 3 and 6 h post DHA exposure. Up-regulated genes were
relatively more abundant, reflecting increased transcript levels induced by DHA-treated Dd2R539T parasites vs. Dd2WT parasites as compared to their
respective DMSO controls. Down-regulated genes reflected a reduction in transcription or faster turnover of these transcripts in DHA-treated Dd2R539T
parasites vs. Dd2WT parasites, compared to their DMSO controls. Gene sets in bold or labeled as # were differentially expressed over the 48 h period of
sampling or between DHA-treated Cam3.IIR539T parasites vs. isogenic Cam3.IIWT parasites respectively (see Supplementary Data 7 for pathways and
genes).
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cell-cycle regulators, which may be important for the parasite’s
exit from a temporary state of DHA-induced quiescence. Our
data suggest that in WT parasites DHA causes a shutdown of
energy-related processes. In contrast, processes including synth-
esis of ATP and vesicular transport across the ER, Golgi, and
plasma membranes can remain transcriptionally active in
resistant K13 mutant parasites even as early as 6 h post DHA
exposure and can be sustained up to 48 h post DHA removal.
Higher expression of membrane-bound transporters and the ATP
synthase complex subunits might reflect the enhanced ability of
K13 mutants to maintain their intracellular pH gradients and
ATP levels following DHA-induced oxidative stress.
Multi-omics results associate K13 with mitochondria-related
energetic processes. Given our multi-omics results that linked
K13 to mitochondrial and purine metabolism (Fig. 2d and Fig. 3a,
c, d), we assessed the susceptibility of K13 mutant and WT
parasites to a panel of mitochondrial and purine metabolism
inhibitors (Fig. 5a). Dose–response assays showed that Cam3.
IIR539T and Cam3.IIWT parasites had equivalent sensitivities to
inhibitors of mitochondrial protein synthesis (fusidic acid), pur-
ine metabolism (immucilin G and H and ribavirin), or pyrimidine
metabolism (the DHODH inhibitor DSM265). These results were
obtained in both 4 h assays that measure activity against early
rings and 72 h standard assays (Fig. 5b and Supplementary
Fig. 9a). In contrast, with the slower-acting mitochondrial ETC
inhibitor atovaquone44,45 (ATQ), we noted a subtle yet statisti-
cally significant 1.6-fold increased sensitivity in Cam3.IIR539T
rings as compared with isogenic Cam3.IIWT rings (shown as
lower IC50 and IC90 values in Fig. 5b). Individual IC50 and IC90
data are provided in Supplementary Data 8.
K13 mutant parasites exhibit differential responses to atova-
quone plus DHA. We next performed drug combination assays
by exposing tightly synchronized early ring-stage parasites to
varying concentrations of both DHA and ATQ, as determined by
molar ratios of their individual IC50 values. Dose–response curves
with early rings exposed for 4 h to increasing ratios of ATQ:DHA
showed evidence of increased ATQ sensitization of Cam3.IIR539T
but not Cam3.IIWT parasites to DHA (Fig. 5c, d). At a 4:1 ATQ:
DHA ratio, the Cam3.IIR539T parasites became fully sensitive to
DHA. Isobologram analyses of the 4 h pulsed ATQ and DHA
drug-pair combination assays revealed moderate synergy in
Cam3.IIR539T, whereas an additive interaction was seen in the
DHA-sensitive Cam3.IIWT line as well as the Cam3.IIC580Y line
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Fig. 5 Multi-omics data and dose–response assays reveals K13′s role in maintaining mitochondrial ETC functions. a Schematic of the energy and purine
metabolism pathways in the parasite mitochondrion. Genes, proteins, metabolites, and co-IP proteins that were detected as differentially regulated
between isogenic K13 mutant and WT parasites in multi-omics experiments are highlighted. ADA adenosine deaminase, DHODH dihydroorotate
dehydrogenase, DLST dihydrolipoyllysine-residue succinyltransferase, HGXPRT hypoxanthine-guanine-xanthine phosphoribosyltransferase, IMPDH
inosine 5′-monophosphate dehydrogenase, PNP purine nucleoside phosphorylase. For full list of protein names, refer to Supplementary Data 5. b IC50 and
IC90 fold shifts for Cam3.IIR539T vs. Cam3.IIWT 0–3 hpi early rings exposed for 4 h to a panel of inhibitors targeting mitochondrial processes (atovaquone,
DSM265, fusidic acid) or purine metabolism (immucilin G and H, ribavirin). Shown are means ± SEM values from two to five independent experiments with
technical duplicates. **P= 0.008, *P= 0.024, two-tailed one-sample t-tests of the IC fold shift. Individual IC50 and IC90 data are provided in
Supplementary Data 8. c Four hour dose–response assays conducted on Cam3.IIWT 0–3 hpi early rings, depicting no change in the DHA dose–response
curves in the presence of increased ATQ to DHA ratios. d Four hour dose–response curves show increased sensitization of Cam3.IIR539T 0–3 hpi early rings
to DHA with higher ratios of ATQ to DHA. The mitochondrial ETC inhibitor ATQ displays increased potency when combined with DHA against Cam3.
IIR539T parasites in 4 h drug treatments. Dose–response assays were performed in three to five independent experiments with technical duplicates for each
parasite line. The data presented in c and d are exemplars from one independent experiment with error bars representing the SD between technical
duplicates. Also see Supplementary Fig. 9b–e for FIC50 curves and isobologram analyses.
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Fig. 9b). This synergy was reflected in a significantly lower
Combination Index (the averaged sum of fractional IC50 (FIC50)
values), in Cam3.IIR539T compared to Cam3.IIWT parasites
(Supplementary Fig. 9b, inset). In 72 h assays, an antagonistic
relationship between ATQ and DHA was observed, with its effect
being most pronounced in WT parasites and less so in C580Y and
especially R539T parasites (Supplementary Fig. 9c). These results
were reproduced, albeit to a lesser degree, in Dd2 parasites that
carry the same K13 genotypes and that are comparatively less
DHA-resistant than the Cam3.II lines (Supplementary Fig. 9d, e).
These results suggest that ATQ-mediated inhibition of the
mitochondrial cytochrome bc1 Qo site can reduce the recovery of
K13 mutant ring-stage parasites following treatment with pro-
oxidant ART drugs.
Discussion
Our multi-omics analysis of isogenic P. falciparum lines expres-
sing mutant or WT isoforms of the ART resistance determinant
K13 reveal a striking array of physiological processes in asexual
blood stage parasites that are uniquely altered by K13 mutations
(Fig. 6). First, cell-cycle periodicity was differentially impacted.
The parasite’s developmental progression decelerated during the
ring stage in the C580Y mutant but not in the R539T mutant.
This contrasted with K13 protein levels that were not significantly
altered in the C580Y mutant yet were lower in the R539T mutant.
Recent reports highlight an association between K13 inactivation
and lowered endocytosis, where less host hemoglobin is taken in
and digested, resulting in less liberation of Fe2+-heme and
reduced ART activation27,28,46. Based on our findings, reduced
endocytosis could stem from either lowered K13 protein levels
and activity in the R539T mutant or prolonged ring development
caused by the C580Y mutation. Upon DHA exposure, K13
mutant trophozoites were earlier reported to show net reductions
in heme-DHA adducts, relative to WT counterparts39,47. Our
observation that fewer genes were DE in DHA-treated K13
mutant parasites, as compared to DHA-treated isogenic WT lines,
supports the hypothesis that a lower level of activated ART
accumulates and exerts its effect in K13 mutant parasites. How-
ever, this did not account for the increased rates of survival of
DHA-treated rings (0–6 hpi) elicited by K13 mutations and the
re-initiation of growth after a temporary arrest, implicating a role
for additional survival mechanisms. Furthermore, in our study
the reduction in hemoglobin-derived peptides upon treatment
with DHA, observed within 3 h of drug exposure, occurred to a
similar degree in both K13 mutant and WT parasites. These
results suggest that the mechanism of ART resistance afforded by
mutant K13 extends beyond a role for reduced hemoglobin
endocytosis in rings.
Our transcriptomic analysis revealed that in the absence of
DHA, nearly 400 genes were DE in Dd2R539T and Dd2C580Y
mutant parasites as compared to isogenic Dd2WT parasites, across
the 48 h IDC. The largest number of DE genes was observed in
newly invaded rings, when K13 mutations impart ART resistance.
Among these genes, most were up-regulated in the mutants. Gene
set enrichment analysis revealed up-regulation of pathways
involved in post-translational modifications (including phos-
phorylation and palmitoylation), protein export or turnover, lipid
metabolism and transport, and the mitochondrial ETC. Many of
these pathways were conserved between Dd2 and Cam3.II para-
sites, although individual genes often differed, suggesting that the
genetic background influences the impact of K13 mutations on
the parasite transcriptome. These data provide evidence for
pleiotropic effects of mutant K13 that are common across parasite
strains. Other loci must nonetheless be important in determining
the extent to which mutant K13 mediates ART resistance. This is
shown by the greater levels of RSA survival in Cam3.II parasites
compared to Dd2 (40.2% vs. 19.4% for the two respective R539T
mutants16), suggesting that K13 also has epistatic interactions
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Fig. 6 Proposed model for the role of K13 in ART resistance. K13 mutations are associated with an up-regulation of protein folding as well as proteasome-
linked protein turnover that may provide a growth advantage via a greater capacity of the mutant parasite to target and eliminate damaged proteins caused
by the proteotoxic ART drug. K13 also appears to be involved in other novel pathways including intracellular signaling, pyruvate metabolism, purine salvage,
and the mitochondrial electron transport chain (ETC). These functions suggest an altered central carbon metabolism and represent a quiescent state
maintained by the parasite that allows for a recovery advantage following DHA exposure. DHA inhibits hemoglobin uptake or degradation and induces
stalling in both K13 mutant (MUT) and wild-type (WT) rings. Recovery in K13 mutants may occur through enhanced mitochondrial ATP metabolic function
and remodeling of the parasite’s secretory and vesicular transport processes. Inhibition of mitochondrial ETC activity lowers the survival of K13 mutant
parasites to DHA treatment.
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were recently found to carry mutant alleles of DNA repair genes
that provided enhanced protection against artesunate-mediated
DNA damage; several of these genes are also present in Dd2
(ref. 48). Other studies have also reported founder genetic back-
grounds on which mutant K13 evolved in Southeast Asia, sup-
porting a role for epistatic interactions that contribute to the
resistance phenotype and that may help with a process referred to
as cellular healing in ART-treated K13-mutant parasites17,49,50.
K13 C580Y and R539T mutations showed very similar impacts
on both parasite transcription and translation in untreated
parasites. Transcriptomics and proteomics results overlapped in
the up-regulation of chaperone-mediated protein folding and the
ubiquitin–proteasome system, as observed in rings of ART-
resistant K13-mutant clinical isolates sampled ex vivo29. The
higher protein abundance of the protein folding factor cyclophilin
19B in K13 mutants reaffirms its earlier report as the top-ranked
transcriptional marker in K13 ART-resistant isolates29 and sug-
gest its involvement in enhancing the parasite’s capacity to sur-
vive the general proteotoxic effects of ART action. In considering
these data, we note that experiments had a limited number of
independent repeats (generally two) and did not include reference
pools or labeling efficiency tests. High reproducibility was
nonetheless observed between repeats (Fig. 3a and Supplementary
Fig. 3b).
Our combined transcriptomics, proteomics and metabolomics
data uncovered new functional modules associated with K13
mutants, including pyruvate and glutamate-linked carbon meta-
bolism, purine metabolism, the mitochondrial ETC, and the TCA
cycle (Figs. 5a and 6). Pyruvate and glutamate metabolism are
highly connected with mitochondrial functions. Pyruvate meta-
bolism is a core energetics pathway that provides acetyl-coA for
the TCA cycle, histone acetylation, and lipid metabolism51,52.
Pyruvate and aspartate synthesis can compensate for deficiencies
in ETC and membrane potential generation in mammalian
cells53. Glutamate is a branch point for carbon and nitrogen
metabolism, feeding into the mitochondrial TCA cycle via its
conversion into 2-ketoglutarate or into glutamine for nitrogen
storage, in preparation for starvation conditions. Our findings of
reduced levels of the mitochondrial TCA cycle intermediates
malate and 2-ketoglutarate in K13 mutants are consistent with
recent modeling predictions based on transcriptional analysis of
ART-resistant versus -sensitive clinical isolates54. In rodent
Plasmodium parasites, the addition of malate or succinate pro-
motes oxygen consumption, which contributes to the mito-
chondrial membrane potential (ΔΨ) and stimulates complex III
activity55,56. The lower levels of malate observed in our meta-
bolomics data suggest that K13-mutant rings might mimic a state
of anoxia and lower the ETC complex III activity. Collectively,
these findings point towards a rewiring of the energy require-
ments and metabolic state in K13 mutant parasites, and suggest
that a higher reliance on reverse glutaminolysis with altered
glycolysis/gluconeogenesis, and lowered mitochondrial TCA cycle
and ETC functions, might facilitate the recovery of DHA-treated
K13-mutant rings. One question that merits further exploration is
whether the reported impact of K13 mutations on reducing
hemoglobin endocytosis27,28 might trigger a semi-starvation state
that accounts for some of our observed metabolic changes. A
recent study showed that the Cam3.IR539T Cambodian parasite
line16 showed a threefold better rate of recovery following 72 h of
isoleucine starvation as compared with the isogenic Cam3.IWT
Cambodian parasite line, suggesting that K13-mutant parasites
might be better able to tolerate semi-starvation57. Nonetheless,
transcriptomic profiling of amino acid-starved 3D7 WT K13
parasites showed a general slowing of transcription across the
IDC58, without evidence of the specific pathways observed in our
study. Metabolomics data in that study also showed minimal
overlap with our results, suggesting that mutant K13-mediated
reduction in hemoglobin endocytosis does not readily mimic
starvation responses resulting from amino acid deprivation.
Further evidence of mitochondrial-linked function in K13
mutants was seen in K13′s physical interaction with mitochon-
drial factors, which may enable K13 parasites to survive the DHA
pulse by reinitiating growth after a temporary 16 h arrest41. Co-IP
experiments identified PGAM2, the parasite ortholog of PGAM5
that is a substrate of the mammalian ubiquitin ligase complex
involving the K13 ortholog KEAP1 (refs. 59,60). In mammalian
systems, KEAP1 associates physically with NRF2 and PGAM5 on
the outer mitochondrial membrane. Upon stress, the mitochon-
drial unfolded protein response occurs via dissociation of KEAP1
from the NRF2–PGAM5 protein complex, leading to retrograde
signaling from the mitochondria to the nucleus and expression of
antioxidant and stress response genes60. We also observed an
increased expression of redox enzymes 48 h after DHA treatment
in K13 mutant parasites. These findings evoke a potential func-
tional interplay between mitochondrial metabolism, signaling and
the unfolded protein response in P. falciparum. We note that our
co-IP results differ from the set of K13-interacting proteins
identified using a quantitative dimerization-induced bio-ID
approach with GFP-tagged K13 (ref. 27). Partial overlap was
nonetheless observed between our study and a separate report
that used GFP-Trap beads to affinity purify GFP-K13 and then
identified the immunoprecipitated proteins18. These results merit
further investigation using independent approaches such as co-IP
data with antibodies specific to mitochondrial proteins, which we
are to date unable to obtain.
Upon exposure to DHA, survival of K13 mutants was asso-
ciated with a shutdown of core metabolic functions including
protein synthesis, transcription, and glycolysis, accompanied by
sustained elevated RNA expression of specific pathways including
vesicle-mediated intracellular transport and ATP production. The
association with vesicular transport recalls earlier associations
between mutant K13 and amplification of PI3P-positive
vesicles that were postulated to neutralize ART proteotoxicity34.
The speed of re-initiation of transcriptional activity correlated
with the degree of ART resistance afforded by K13 mutations
in the Dd2 and Cam3.II backgrounds. We hypothesize that
this might occur via the regulation of mitochondria-
linked quiescence. This possibility is supported by the greater
extent of sensitization to DHA by ATQ (an ETC complex III Qo
ubiquinol oxidation inhibitor) in the Cam3.II mutants compared
to the Dd2 K13 mutants (that impart lower resistance) or sen-
sitive WT lines.
In the mitochondria of mammalian cells, redox equilibrium is
regulated through functions including oxygen uptake, ATP pro-
duction, maintenance of membrane potential, and generation of
reactive oxygen species. Dysregulation of these processes can
drive cells towards senescence or proliferation52,61. In certain
cancerous states, cells can switch between senescence and pro-
liferation by modulating their reliance on glycolysis vs. oxidative
phosphorylation (involving the TCA cycle and the ETC)52,62,63.
Recent research has described drug-induced “low glycolysis-low
oxidative phosphorylation” phenotypes that enable mammalian
cells to survive drug challenge62. A potential role for mitochon-
dria in sensing ART action and regulating cellular quiescence was
recently evoked in a study with Mycobacterium tuberculosis,
which found that ART can inhibit intracellular signaling and
persistence via adduct formation with heme-carrying kinases that
act as redox or hypoxia sensors64. In P. falciparum, we also
observed substantial mitochondrial oxidation within 4 h of DHA
treatment, at levels considerably greater than those observed with
either chloroquine or ATQ41. Our data suggest a metabolic
rewiring in P. falciparum parasites, with a dysfunctional
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mitochondrion that can be perturbed by combining ATQ with
DHA. Interestingly, a genome-wide CRISPR/Cas9 screen in the
Apicomplexan parasite Toxoplasma gondii recently identified
components of the TCA cycle and heme biosynthesis as mito-
chondrial determinants of DHA susceptibility65. One important
distinction, however, is that unlike Plasmodium, Toxoplasma
parasites do not endocytose or metabolize hemoglobin, thereby
removing this pathway for ART activation. Further studies are
merited to assess whether altered mitochondrial metabolism
might constitute a vulnerability that can be leveraged to overcome
ART resistance.
In summary, our findings suggest that interconnected
mechanisms might poise K13 mutant parasites to survive DHA
treatment and increase the parasite’s proteostatic capacity. These
mechanisms include an enhanced ability to eliminate damaged
proteins through the unfolded protein response and
ubiquitin–proteasomal machinery, and remodeling of secretory
and vesicular transport processes that impacts hemoglobin
endocytosis and protein and lipid trafficking (Fig. 6). K13
mutations may also facilitate rapid recovery post ART exposure
by adjusting their central carbon-linked pyruvate and glutamate
metabolism, and enabling mitochondrial sensing of cellular
damage and the protection and subsequent survival of a subset of
drug-exposed parasites (Fig. 6). Further investigation into these
mechanisms, which will require additional validation, promises to
deliver new approaches to target ART-resistant P. falciparum, a
goal that is increasingly important given the global dissemination
of drug-resistant malaria.
Methods
Parasite lines and culture conditions. P. falciparum parasites were cultured at 3%
hematocrit in human O+ RBCs (Interstate blood bank, USA) and P. falciparum
culture media comprising RPMI 1640 (Thermo Fisher Scientific) supplemented
with 0.5% (w/v) Albumax II, 50 mg/L hypoxanthine, 0.225% NaHCO3, 25 mM
HEPES, and 10 mg/L gentamycin66. Parasites were cultured at 37 °C in 5% O2, 5%
CO2, and 90% N2. Parasite lines were genotyped by Sanger sequencing k13 to verify
their identities before the start of an experiment. Dd2 and Cam3.II parasites were
previously reported16, with Cam3.IIWT earlier referred to as Cam3.IIrev. We note
that Dd2 was adapted to culture in 1980, decades before the introduction of ART
derivatives, whereas Cam3.II was adapted in 2010 a decade after ARTs entered
widespread use in the region16,67.
Sample preparation for microarray-based transcriptomics. To obtain tightly
synchronized parasites, the K13 mutant or WT lines Dd2R539T, Dd2C580Y, Dd2WT,
Cam3.IIR539T, and Cam3.IIWT (Fig. 1) were doubly synchronized with 5% D-Sor-
bitol every IDC cycle for at least three cycles, prior to collecting samples for RNA.
We confirmed that parasite cultures were highly synchronous by microscopy,
which showed that >95% of all parasites were early rings at the start of each time
course experiment. We also computationally assessed transcriptomic profiles by
applying Spearman rank correlation calculations for each parasite sample to
multiple time points across the IDC of a highly synchronized reference tran-
scriptome (see Supplementary Fig. 1b–e). This analysis yielded mean ± SD corre-
lation coefficients of 0.68 ± 0.03 across samples, as expected for highly
synchronized cultures based on our earlier studies68. RSAs with the synchronized
rings used to initiate our transcriptome sampling yielded survival values that
agreed closely with our earlier published data16.
Samples were collected every 8 h throughout the IDC for the Cam3.IIR539T and
Cam3.IIWT lines, and at 0, 3, 6, 24, 32, and 48 hpi for the Dd2R539T, Dd2C580Y and
Dd2WT lines. After washing the packed RBC pellets with 1× phosphate-buffered
saline (PBS) pH 7.4, a 10× pellet volume of TRIzol was added to the pellet and total
RNA was extracted using an acidified phenol-chloroform method69. Total RNA
was reverse transcribed into cDNA using Superscript II reverse transcriptase and
the SMART protocol, with template switching at the cDNA 3′ ends69. The cDNA
was amino allyl-dUTP labeled using 30 cycles of PCR amplification. Four
micrograms of each sample was then labeled with Cy5 fluorescent dyes and mixed
with an equal amount of a Cy3 labeled pool comprising mixed asexual blood stages
of the reference strain 3D7. Samples were hybridized on a custom P. falciparum 70-
mer long oligonucleotide microarray chip containing 11,400 probes (GEO
Platform: GPL18893) at 65 °C for 20 h29. This approach was used to generate
transcriptional profiles for 156 samples and was chosen as a cost-effective
alternative to RNA-seq. Arrays were washed and scanned using the autogain PMT
setting on a Tecan PowerScanner.
Data analyses for transcriptomics. Data processing used GenePix Pro software
(Molecular devices) and the R Bioconductor LIMMA package version 3.10.3. Only
spots with flag >0, and a feature intensity greater than 1.5-fold higher than the
background intensity in either Cy5 or Cy3 channel, were included. Background
correction used the Normexp algorithm and probe ratios were normalized for each
array using the Loess method70. Ratios of all probes mapping specifically to each
gene were averaged to generate a list of gene log2-transformed ratios, representing
the log2 ratio of transcript abundance in the sample to transcript abundance in the
3D7 reference pool. For each individual isolate, treatment condition, and replicate
IDC, we retained genes present in >66% of the time points, i.e. genes were retained
only if they were present in at least 5 out of 7 time points, 4 out of 6 time points, or
8 out of 12 time points. Retained genes also had to be present across the three
independent experiments for each parasite line to avoid bias introduced by
detection in only one biological experiment. Between 19 and 71 genes were filtered
out for each replicate group and these comprised mainly multigene families
including rifins and stevors. Missing data were imputed across all stages and
replicates belonging to a given parasite line, using the KNN function applied to a
nearest neighbor of 10 genes. This method increased robustness with the impu-
tations while maintaining the specificity for each strain. We used the KNN method
to impute missing data, as polynomial fitting or Fast Fourier Transformations did
not produce good fits if values were missing at the starting or end points or if
sample collection was not regularly spaced over time. After imputing missing data,
>4990 (90%) P. falciparum genes were analyzed for each parasite strain and were
annotated accordingly (PlasmoDB v46).
Generating a high-resolution Dd2 reference transcriptome model. Because P.
falciparum gene expression is a sine-wave function, we generated a high-resolution
transcriptome of the reference Dd2 line by interpolating RNA expression of each
gene at 30-min time intervals (from a dataset of samples harvested every 2 h).
These interpolations used linear regression of polynomial fitting with strict cutoffs
of Fisher’s exact test P < 0.001, adjusted R2 > 0.7, and the Bayesian’s Information
Criterion (BIC) to find the optimum degree of fit for each gene. Coefficients of the
polynomial equation were applied to generate log2 expression ratios at 30-min
intervals from 0 to 48 hpi, resulting in 96-time points per gene. In total 4342 genes
that could be fitted into a polynomial curve were obtained for the Dd2 reference
transcriptome. The predicted 96-time point transcriptomes had very high corre-
lations of 0.94 ± 0.05 (mean ± SD) with the actual 24-time-point transcriptomes
sampled across the 24 time points. Applying a filter of max-min expression >2-fold
gave us 3500 genes that each had a clear peak of expression at a particular stage in
the IDC. This was used to calculate the sample age (in hpi) of each parasite sample
time point. Principle component analysis (using the TM4 MeV software version
4.8.1) was performed on each sample to identify underlying variables that con-
tributed to expression differences.
To identify DE genes in the K13 mutant lines across the IDC, we performed
Student’s t-tests with replicates of K13 mutant vs. WT samples or between DHA-
treated and DMSO vehicle-treated samples, using the log2 RNA expression levels at
each sampling time point for rings, trophozoites, and schizonts. To identify genes
that showed a significant difference between the K13 mutant and WT lines in their
transcriptional response to DHA exposure, we applied two-factor ANOVA with
permutations using subtracted log2 RNA expression ratios of drug-treated vs.
DMSO control samples. This was performed in each parasite background across all
sampling time points or at the initial 3 and 6 h treatment time points. Kyoto
Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and Malaria
Parasite Metabolic Pathway (MPMP) gene sets derived from PlasmoDB were used
for functional enrichment analyses of the DE genes by hypergeometric testing, as
described29. DE genes and pathways in K13 mutants vs. WT lines are listed in
Supplementary Data 1 and 2. DE pathways in response to DHA in K13 mutants
and WT lines are listed in Supplementary Data 6 and 7.
Sample preparation for untargeted liquid chromatography-tandem mass
spectrometry (LC-MS/MS) proteomics. Cam3.IIR539T, Cam3.IIC580Y, and Cam3.
IIWT parasites were doubly synchronized using 5% D-Sorbitol for each IDC for at
least 2–3 cycles. Early-mid rings or trophozoites of each parasite line were har-
vested by washing with 1× PBS and then lysed with 0.1% saponin in the presence of
a protease inhibitor cocktail (Roche). For each parasite line, we harvested ring and
trophozoite stages on two independent occasions, except for Cam3.IIC580Y tro-
phozoites that were harvested only once. Parasite extracts were lysed to release
proteins and 600 μg of protein of each sample was digested with trypsin and
processed as described71. Briefly, the saponin-treated parasite pellets were lysed
with TEG buffer (50 mM Tris-HCl, 0.5 mM EDTA, 5% β-glycerol phosphate, 1%
NP-40, pH 7.4) containing protease and phosphatase inhibitors on ice for 10 min.
Samples were centrifuged at 20,000g for 3 min, and the supernatant collected. The
pellet was again resuspended in TEG buffer without NP-40 and sonicated 3 × 15 s
on ice and then centrifuged at 20,000g for 3 min. An additional extraction step was
performed for ring samples where the pellet was resuspended in the TEG buffer
with 2% CHAPS and 0.5% SDS, and sonicated 3 × 15 s on ice and then centrifuged
at 20,000g for 3 min. The two (trophozoite) or three (ring) supernatant fractions
were then combined. Protein concentrations in the final lysates were in the range of
1.2–4.7 mg/mL for rings and 4.3–6.0 mg/mL for trophozoites in a final volume of
0.6 mL. 0.6 mg of protein from each sample lysate was dissolved in 1 mL TEG
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20805-w ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:530 | https://doi.org/10.1038/s41467-020-20805-w |www.nature.com/naturecommunications 11
buffer (10 mM Tris, 5 mM EDTA, 20 mM β-glycerol phosphate, pH 7.4) and
denatured at 37 °C for 30 min in the presence of 10 mM DTT and 0.1% SDS.
Iodoacetamide (1M solution) was then added to a final concentration of 100 mM,
adjusted to pH 8.0, and samples were incubated for 1 h at room temperature in the
dark. Protein was precipitated on ice for 10 min by addition of 100% trichloroacetic
acid (at a ratio of 1:3) to the samples and harvested by centrifugation for 5 min at
2000g followed by two washes with 1 mL TEAB (triethylammonium bicarbonate,
pH 8.5). All washing buffer was removed before the protein pellets were sonicated
in 300 μL of 50 mM TEAB buffer on ice for 3 × 15 s and digested with trypsin
(Promega) at a ratio of 1:20 (w/w) trypsin to protein content, overnight at 37 °C on
a rotating platform. Samples were then concentrated to about 0.3–0.5 mL in a
Speedvac centrifuge.
For each LC-MS/MS experiment, each parasite line was labeled with a unique
isobaric tag (tandem mass tag, TMT 6-plex) and pooled to allow direct
comparisons of the proteomic levels of the K13 mutants vs. WT samples. Given the
small number of samples, it was not possible to introduce a complete
randomization. Instead, we assigned different tags to different samples and runs, as
detailed in our data deposited to the ProteomeXchange Consortium (see Data
availability section below). Reference pools were not used to internally normalize
samples. The experimental design flow chart is shown in Fig. 1. After incubation
with TMT reagents, the labeled samples were pooled and concentrated to a volume
of 1.2 mL in a Speedvac centrifuge, then mixed with 0.3 mL of 100% acetonitrile
and diluted with 10 mM TEAB, pH 8.0 to a final volume of 3 mL. Samples were
fractionated using a Resource Q anion-exchange column (GE Healthcare). Peptides
were eluted by a linear gradient of 0–1M NaCl in 10 mM TEAB, pH 8.0, collecting
1 mL fractions. The fractions were concentrated and run on the LTQ-Orbitrap-
Velos mass spectrometer (Thermo Scientific). The raw data file was processed
using Proteome Discoverer version 2.1 (Thermo Fisher Scientific), searching each
file using Mascot version 2.6.0 (Matrix Science Ltd.) against the UniProtKB-Swiss
Prot database or a decoy database. To minimize variability, samples were combined
on a single MS/MS run. Of note, we identified very few peptides that lacked a TMT
tag. Given the abundance of tagged peptides, we estimated the labeling efficiency as
>99%.
Data analysis for proteomics. Scaffold Q+ (version Scaffold 4.8.2, Proteome
Software Inc., Portland, OR) was used to quantify TMT label-based peptides. We
applied the following criteria to confidently assign proteins and generate the global
protein expression levels. Peptide identifications were accepted if they could be
established at >95% probability. Peptide probabilities from X! Tandem were
assigned by the Peptide Prophet algorithm72 with Scaffold delta-mass correction.
Protein identifications were accepted if they could be established at >48% prob-
ability to achieve a false discovery rate <1.0%, and contained at least one identified
peptide unique to the assigned protein. Protein probabilities were assigned by the
Protein Prophet algorithm version 5.0 (ref. 72). Proteins that contained similar
peptides and could not be differentiated based on MS/MS analysis alone were
grouped to satisfy the principles of parsimony. Normalization of ion intensities was
performed iteratively across samples and spectra, using an ANOVA model to
account for variability across MS acquisitions and between channels, as descri-
bed73. Spectra data were log-transformed, pruned of those that matched to multiple
proteins, and weighted by an adaptive intensity weighting algorithm. We then
applied an iterative normalization procedure for each run. Individual quantitative
samples were median-normalized within each acquisition run. Intensities for each
peptide identification were normalized within the assigned protein. Supplementary
Figure 10 shows the distribution of reporter ion intensities across the TMT
channels for each of the four LC-MS/MS runs using Cam3.IIR539T, Cam3.IIC580Y,
and Cam3.IIWT K13 ring and trophozoite stage parasites.
For every sample, we first removed poor quality spectra (large spectral count
variation) within a protein if the standard deviation in normalized intensities was
greater than the mean ± 2 SD (standard deviations) for experiments with 6-plex
TMT (since intensity between spectra should be similar for a protein). If TMT= 3,
we removed bad spectra where the SD of the log2 fold change across spectra was
greater than the median log2 fold change (assuming that differences between
strains were consistent with a small SD). On average, for each run 29,259 high-
quality spectra (86% of total) were included in the final quantitation. We obtained
the median log2 normalized spectral intensities of exclusive peptides for each
protein. In every biological experiment, DE proteins were identified based on
performing a t-test for each individual protein between the K13 mutant and WT
samples. The log2-transformed fold change of the normalized intensities was used
to plot the heat maps for each protein. See Supplementary Data 3 for protein
expression levels.
Co-IP and mass spectrometry with monoclonal anti-K13 antibodies. Antibodies
were raised against recombinant K13 protein by injecting mice intraperitoneally
with two types of immunogens: the BTB-propeller domain (~40 kDa) or the
propeller domain only (~32 kDa), as described41. Immunoprecipitation (IP) studies
were performed using the direct IP kit (Fisher Scientific) according to the manu-
facturer’s instructions. Briefly, parasites were released from infected RBCs using
0.05% saponin in PBS and were washed twice in PBS. Pelleted parasites were then
resuspended in Pierce IP Lysis Buffer supplemented with 1× Halt Protease and
Phosphatase Inhibitor Cocktail and 25 U Pierce Universal Nuclease, and lysed on
ice for 10 min with frequent vortexing. Samples were centrifuged at 18,400g for 10
min at 4 °C to pellet cellular debris. Supernatants were collected and protein
concentrations therein were determined using the DC protein assay kit (Bio-Rad).
IPs were performed used 500 μg of lysate per test sample. A mix of K13 monoclonal
antibodies E3 and D9 (2.5 μg each per test sample) was used for IP. Antibody
coupling to IP columns, IP, and elution steps were performed according to the
manufacturer’s instructions. Eluates were analyzed by LC-MS/MS to identify
immunoprecipitated proteins.
Analysis of K13 protein interactions. We filtered for proteins that were detected
with at least three peptide counts in at least three out of six independent co-IP
experiments and present in more than 35% samples (5 out of 13 samples). STRING
version 11.0 based on seven datasets (textmining, experiments, databases, co-
expression, neighborhood, gene fusion, and co-occurrence) was used to generate an
interactome of the 21 proteins found to interact with K13. We applied an inter-
action confidence cutoff of 0.4 and a Markov Clustering with an inflation score of
3. These 21 proteins are listed in Supplementary Data 5.
Sample preparation for untargeted LC-MS metabolomics. Testing for Myco-
plasma was performed using a MycoAlert PLUS Mycoplasma Detection Kit
(Lonza) prior to the start of the sample collection. Mycoplasma-free Cam3.IIC580Y
and Cam3.IIWT parasites were doubly synchronized by 5% D-sorbitol in each
generation for at least two generations. In all, 0–3 hpi early rings of each parasite
line were treated for 3 h at 70 nM or 350 nM DHA along with vehicle-treated 0.05%
DMSO controls in two to three independent experiments with one to three tech-
nical replicates. Twenty-four hpi trophozoites were similarly treated with DHA or
DMSO control in a single experiment with six technical replicates for each parasite
line and were subsequently magnetically enriched using MACS CS columns on the
SuperMACS™ II Separator (Miltenyi Biotec, Inc.) to remove uninfected RBCs. This
protocol followed standard conditions previously used to study the metabolomes of
Pf parasites exposed to various antimalarial agents40. The K13 mutant and WT
ring-stage parasites were run in parallel for each metabolomic experiment to allow
direct comparisons of their metabolomic states and the effects of DHA. Metabolites
were examined from the saponin-lysed parasites and not from the culture media.
Metabolites from saponin-lysed parasites were extracted as described40. Briefly,
parasites were lysed in 1 mL of 90% cold methanol, containing 0.5 µM of the
internal standard [13C4, 15N1]-Aspartate (Cambridge Isotope) to correct for tech-
nical variation arising from sample processing in the data analysis phase. Samples
were vortexed and centrifuged to remove cell debris. The clarified supernatants
were dried under nitrogen prior to resuspension in HPLC-grade water (Chroma-
solv; Sigma) for LC-MS analysis. Samples were randomized and 10 μL of extract or
processing blank was injected for analysis. Metabolites were analyzed using a
previously established reversed phase ion-paired method on a Thermo Exactive
Plus Orbitrap LC-MS, scanning from 85 to 1000 m/z (R= 140,000) and operating
in negative ESI mode74,75. Metabolite separation was achieved on a Synergy Hydro-
RP column (100 × 2mm, 2.5 µm particle size; Phenomenex, Torrance, CA). Solvent
A was 97:3 water:methanol with 10 mM tributylamine and 15 mM acetic acid, and
solvent B was methanol (all solvents were HPLC grade).
Data analyses for metabolomics. Data analysis was performed as described40.
Briefly, raw data files from the Thermo Exactive Plus orbitrap (.raw) were con-
verted to a format compatible with our analysis software (.mzXML) and spectral
data (.mzXML files) were visualized in MAVEN version 8.0.3 (ref. 76). The labeled
[13C4, 15N1]-Aspartate internal standard intensity was assessed for technical
reproducibility. Metabolites (level 1 annotation) were identified using an in-house
database/library generated from pure standard compounds processed on the same
LC-MS platform40. The criteria for positive identification was based on peak
proximity to standard retention time, the observed mass falling within 10 ppm of
the expected m/z (calculated from the monoisotopic mass), and the signal/blank
ratio (minimum of 10,000 ions). Based upon the above criteria, peaks were further
manually inspected and demarcated as good or bad based on peak shape. Peak
areas were exported into an R working environment (http://www.R-project.org) to
calculate log2 fold changes for each sample compared to control. Metabolites that
were not reliably detected across trials were removed prior to additional analysis to
minimize the number of “0” values and subsequent imputation bias. The peak areas
for any remaining metabolites not detected (“0” value) were imputed to have
10,000 ions, and metabolites that were negative after blank subtraction (sample
area < blank area) were maintained as “0” prior to averaging and log2 calculation.
To investigate the effect of K13 mutations on P. falciparum physiology, the log2
fold change of mutant vs. WT metabolites was calculated for each experimental run
using the technical replicate peak areas. Three independent experiments, with two
to three technical replicates for samples without DHA treatment and one to three
replicates for samples after pulsing with DHA, were conducted with ring stages of
Cam3.IIC580Y and Cam3.IIWT parasites. Spectral data for each technical replicate
peak area across all independent trials are listed in Supplementary Data 4. To
examine the effects of K13 mutation, we applied metabolomic set enrichment
analyses and partial least-squares discriminant analyses (MetaboAnalyst 3.0
package in R). For DHA treatments, the spectral peak areas were averaged and
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divided by the average of the DMSO controls for each sample type. Data were log2
transformed to obtain a single log2 fold change for each sample.
Drug susceptibility assays. Drug stocks of DHA, atovaquone, fusidic acid,
ribavirin, and immucilins G and H were made in dimethyl sulfoxide (DMSO) or
ultrapure water (immucilins exclusively), and aliquots were stored at −20 °C. All
drug assays were conducted such that the final DMSO concentration was <0.5%.
Except for immucilins, all assays used standard media as described above. For
immucilin assays, we first adapted parasites to low 10 μM hypoxanthine media, as
high hypoxanthine levels have been shown to artificially elevate the IC50 values of
purine salvage inhibitors. We also used blood washed several times in low
hypoxanthine media. For standard IC50 dose–response assays, ring-stage cultures at
0.4% parasitemia and 1% hematocrit were exposed for 72 h to a range of 10 drug
concentrations that were twofold serially diluted, along with drug-free controls.
The IC50 defines the drug concentration that results in 50% inhibition of parasite
growth. IC50 can also be reported in the literature (e.g. ref. 24) as EC50. In the 4 h
pulsed drug assays, we obtained 0–3 hpi young rings using Percoll-Sorbitol syn-
chronization77 and exposed these to the panel of inhibitors. At the end of the pulse,
drug was removed by carrying out three washes and a plate transfer using a Tecan
EVO 100 automated liquid handler, and parasites were cultured for another 68 h.
At least three independent biological replicates were performed, each with technical
duplicates. Parasite survival was assessed on an Accuri C6 flow cytometer (BD
Biosciences) using SYBR Green I and MitoTracker Deep Red FM (Thermo Fisher
Scientific) as stains for DNA and cell viability, respectively. Flow counts were
analyzed by gating the live parasites using FlowJo software (FlowJo LLC) as illu-
strated in Supplementary Fig. 11. Percent parasite survival (normalized to 100%)
was plotted against log drug concentrations. A nonlinear regression model was
used to determine IC50 values (GraphPad Prism). Statistical analyses by one-sample
t-tests were used to determine whether there was a significant difference in the
response of K13 mutant and WT parasites to these individual compounds.
Drug-pair combination susceptibility assays. Parasites were exposed for 4 or 72
h to a range of ten twofold serially diluted concentrations of atovaquone plus DHA,
applied in fixed molar ratios (1:0, 4:1, 2:1, 1:1, 1:2, 1:4, 0:1) of their individual IC50
values. For the isobologram analyses, we calculated the fractional IC50 values of the
fixed ratios of drug combinations vs. DHA or atovaquone alone. The Combination
Index for the Loewe Additivity was also used to determine whether the relationship
between DHA and the test inhibitor was synergistic, additive, or antagonistic.
Paired t-tests were used to test for a difference in the combination index values
between each mutant and WT line.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Microarray gene expression data are available in NCBI’s Gene Expression Omnibus with
the identifier GSE151189. Data for mass spectrometry proteomics are available in
ProteomeXchange Consortium (http://www.proteomexchange.org/) via the PRIDE
repository database with the dataset identifier PXD019612 and https://doi.org/10.6019/
PXD019612 (https://www.ebi.ac.uk/pride/archive/projects/PXD019612). LC-MS/MS
metabolomics data are available at the NIH Common Fund’s National Metabolomics
Data Repository (NMDR) website, the Metabolomics Workbench (https://www.
metabolomicsworkbench.org) with the project ID PR000864, and https://doi.org/
10.21228/M80T2X. Datasets extracted from PlasmoDB (https://plasmodb.org), Kyoto
Encyclopedia of Genes and Genomes (https://www.genome.jp/kegg/), Gene Ontology
(http://geneontology.org/), Malaria Parasite Metabolic (https://mpmp.huji.ac.il/), and
STRING (https://string-db.org/) can be accessed using these weblinks. The authors
declare that all other data supporting the findings of this study are available within the
paper and its Supplementary Information files. Requests for resources and reagents
should be directed to D.A.F. (df2260@cumc.columbia.edu). Source data are provided
with this paper.
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